Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mylan's Coury on Teva: deal 'without logic'

This article was originally published in Scrip

Executive Summary

"Such a combination is without sound industrial logic or cultural fit." So said Mylan's executive chairman Robert Coury in response to speculation over a potential bid for the company by rival Teva Pharmaceutical Industries. He said Mylan had studied the potential combination of the two companies "for some time", and added that it was unlikely it would obtain antitrust clearance given the "significant overlap" in their businesses.

Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts